Laboratory Form PH Critical Values
Effective Date: 05.02.2017
Review Date: 05.09.2017
Associated Policy: Laboratory General Policy
RESPONSIBLE POSITIONS:
1. Laboratory Workforce
2. Palmetto Health Providers
LABORATORY ADDRESSES:
Palmetto Health Richland
5 Richland Medical Park Drive
Columbia, SC 29203
Palmetto Health Baptist
Taylor at Marion Street
Columbia, SC 29220
Palmetto Health Baptist Parkridge
400 Palmetto Health Parkway
Columbia, SC 29212
Palmetto Health Toumey
129 North Washington Stress
Sumter, SC 29150
Chemistry and Immunoassay
Less Than/Equal To
Greater Than/Equal To
NA
NA
109 umol/L
200 umol/L
NA
NA
NA
NA
6.0 mg/dL
0.78 mmol/L
10 mmol/L
10 mmol/L
6.0 mg/dL
15.0 mg/dL
18.0 mg/dL
15.1 mg/dL
13.0 mg/dL
1.58 mmol/L
40 mmol/L
NA
NA
NA
NA
15.0 mg/dL
4.0 mg/dL
9.0 mg/dL
40 mg/dL
40 mg/dL
40 mg/dL
201 mg/dL
400 mg/dL
501 mg/dL
40 mg/dL
40 mg/dL
40 mg/dL
201 mg/dL
400 mg/dL
501 mg/dL
Ammonia:
0-17 Yrs.
>/= 18 Yrs.
Bilirubin, Total:
0-1 Day:
1-3 Days:
3-30 Days:
>=1 Mos:
Calcium, Total
Calcium, Ionized
CO2 >/= 1 mos.
<1 month
Creatinine
>/=19 Yr.
0-18 Yr.
Bilirubin, Direct
Glucose
0-60 days
61 days- 17 Yr.
>/=18 Yr.
Glucose, Post Prandial
0-60 days
61 days- 17 Yr.
>/=18 Yr.
Page 1 of 49
Laboratory Form PH Critical Values
Chemistry and Immunoassay
Lactic Acid
Magnesium
Male >/= 18 Yr.
Male 0-17 Yr.
Female >/= 18 Yr.
Female 0-17 Yr.
Osmolality (Serum)
Phosphorus:
Potassium:
0-5 mos.
>/= 6 mos.
Procalcitonin
Sodium:
0-30 Days
31 Days - 12 years
>/=13 years
Troponin
Uric Acid
Less Than/Equal To
NA
Greater Than/Equal To
5.0 mmol/L
1.0 mg/dL
1.0 mg/dL
1.0 mg/dL
1.0 mg/dL
240 mOsm/kg
1.2 mg/dL
6.0 mg/dL
5.0 mg/dL
7.0 mg/dL
5.0 mg/dL
350 mOsm/kg
8.9 mg/dL
2.5 mmol/L
2.5 mmol/L
0 ng/mL
7.0 mmol/L
6.5 mmol/L
2 ng/mL
125 mmol/L
125 mmol/L
120 mmol/L
150 mmol/L
160 mmol/L
160 mmol/L
0.30 ng/mL
12.1 mg/dL
Chemistry Therapeutic Drugs
Greater Than/Equal To
Acetaminophen
Alcohol
Amikacin Peak
Amikacin Trough
>/=3 months
0-2months
Carbamazepine(Tegretol)
Cyclosporine
Dilantin, Total
Dilantin, Free
Digoxin
Gentamicin Peak
Gentamicin Trough
>18 years
3m-18yrs
0-2 months
Lithium
Phenobarbital
Salicylate
Tacrolimus
Theophylline
151 ug/mL
300 mg/dL
40.1 ug/mL
10.1 ug.mL
7.00 ug/mL
15.1 ug/mL
500 ng/mL
30.1 ug/mL
4.1 ug/mL
2.1 ng/mL
12.1 ug/mL
2.1 ug/mL
2.5 ug/mL
1.2 ug/mL
1.6 mmol/L
41 ug/mL
41 mg/mL
25.0 ng/mL
25.1 ug/mL
Page 2 of 49
Laboratory Form PH Critical Values
Tobramycin Peak
15.1 ug/mL
Chemistry Therapeutic Drugs
Greater Than/Equal To
Tobramycin Trough
0-2 Mos.
3 Mos.-17 Yrs.
Valproic Acid
Vancomycin Trough
0-18 years
>18 years
Vancomycin Peak
1.2 ug/mL
2.5 ug/mL
201 ug/mL
25.0 ug/mL
40.1 ug/mL
70.1 ug/mL
Coagulation
Less Than/Equal To
Greater Than/Equal To
Antithrombin III
Fibrinogen
INR
PT
PTT
50%
100 mg/dL
NA
NA
NA
NA
NA
4
200
150.0 seconds
Flow Cytometry
Fetal Hgb Flow Marker
≥0.30%
Hematology
Less Than/Equal To
Greater Than/Equal To
9.6 g/dL
5.5 g/dL
NA
NA
25%
18%
65%
60.00%
2.0 K/uL
1.0 K/uL
50.1 K/uL
75.0 K/uL
50 K/uL
1,000 K/uL
20 K/uL
1,000 K/uL
Hemoglobin
(0-1 mos)
(>1 mos)
Hematocrit
(0-3 mos)
(> 3 mos)
WBC
(0-3 mos)
(> 3 mos)
Platelet Count
(0-2 mos)
(> 2 mos)
Page 3 of 49
Laboratory Form PH Critical Values
Immunology
Bacterial Antigen Detection, Rapid Test for:
Legionella urinary antigen
Positive
Streptococcus pneumonia antigen
Positive
Immunology
Cryptococcal Antigen (CSF or Serum)
Heparin Induced Platelet Antibody
HIV, Rapid test
Positive
Positive
Positive
Microbiology
Carbapenemase Isolates
C difficile toxin A/B
Cultures from:
Tissue Samples from OR to include bone
and cornea samples
Blood Cultures
Stool for Parasites
Cultures for :
Acid Fast Bacteria (AFB)
Bordetella
Haemophilus influenzae (Invasive)
Listeria
Neisseria gonorrheae
Neisseria meningitidis
Streptococcus pneumoniae (Invasive)
Salmonella
Shigella
Campylobacter
E coli 0157:H7
India Ink Prep
Smears for:
Acid Fast Bacteria (AFB)
Smears from:
CSF
Blood
Body Cavity
Tissue Samples from OR (to include
bone and cornea samples
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Page 4 of 49
Laboratory Form PH Critical Values
Molecular Pathology
Bordetella pertussis DNA
Positive
Parasitology
Malaria Smears
Pathologic parasites from O&P exam
Positive
Present
Reference Lab
Western Blot
Positive
Other Reference Lab Critical value results as determined by the reference lab will be called by the
reference lab to the Palmetto Richland Lab. Palmetto Richland Lab will then call the panic value
result per lab policy.
Page 5 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
Effective Date: 06.13.2017
Review Date: 06.13.2019
Associated Policy: Laboratory General Policy
Associated PGR:
RESPONSIBLE POSITIONS:
Laboratory Workforce
Palmetto Health Providers
LABORATORY ADDRESSES:
Palmetto Health Richland Central Laboratory Palmetto Health Richland Rapid Laboratory
14 Richland Medical Park Drive
5 Richland Medical Park Drive
Columbia, SC 29203
Columbia, SC 29203
Palmetto Health Baptist Laboratory
Taylor at Marion Street
Columbia, SC 29220
Palmetto Health Baptist Parkridge Laboratory
400 Palmetto Health Parkway
Columbia, SC 29212
Palmetto Health Toumey
129 North Washington Stress
Sumter, SC 29150
PROCEDURE:
REFERENCE:
Acetaminophen (Therapeutic) ug/mL
10-30 ug/mL
Acetone
Negative
Activated Protein C Resistance
>1.84
Adenovirus Rapid
Negative
Albumin g/dL:
0 Days - 1 Year
1 Year - 6 Years
6 Years - 11 Years
11 Years - 15 Years
15 Years - 21 Years
21 Years - 61 Years
>=61 Years
2.8-4.7
3.5-4.7
3.6-4.7
3.7-4.8
3.4-4.9
3.5-5.0
3.4-4.8
Page 6 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
REFERENCE:
Albumin Body Fluid g/dL
The separation of ascitic fluids into transudates or
exudates has been superseded by the division of ascitic
fluids into high-gradient or low-gradient fluids as
determined by the serum-ascities albumin gradient
"calculated as (serum albumin) - (ascitic fluid
albumin). The gradient is a reflection of the
hydrostatic pressure in the portal circulation.
Gradients >/=1.1 g/dL are considered high. Specimens
of serum and fluid should be drawn the same day. High
Values may be seen in: Cirrhosis, Fulminant hepatic
failure, Fatty liver, Alcoholic hepatitis, Portal vein
thrombosis, Ven-occlusice disease; Low Values may
be seen in Peritoneal arcinomatosis, Tuberculosis,
Pancreatic, Connective tissue disease, Neprotic
syndrome, Biliary (without cirrhosis). Pleural Fluid:
Serum Albumin Level - Pleural Fluid Albumin Level
</=1.2 g/dL is predictive of an exudate.
Alcohol (ETOH) mg/dL
Alcohol (ETOH) g%:
0-21 Years SC Legal limit
>21 Years SC Legal limit
<30
Alkaline Phosphatase U/L:
Male and Female:
0 Days - 12 Months
1 Year - 6 Years
6 Years - 11 Years
Male:
11 Years - 15 Years
15 Years - 21 Years
Females:
11 Years - 15 Years
15 Years - 21 Years
Male and Female:
>/= 21 Years
<0.019
<0.079
150-507
152-767
135-537
92-549
62-369
50-415
47-175
40-150
Alpha 1 Antitrypsin mg/dL
90-200
Alpha Fetoprotein Tumor Marker ng/mL
<8.79
Page 7 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
ALT (SGPT) U/L:
Male and Female:
0 Days - 12 Months
1 Year - 6 Years
Male:
6 Years - 11 Years
Female:
6 Years - 11 Years
Male and Female:
>/= 11 Years
REFERENCE:
Amikacin Level ug/mL
Apply to nomogram. Please contact pharmacy with
questions.
9-39
9-59
9-69
<37
<55
Amikacin Therapeutic Trough ug/mL:
0 Minutes - 3 Months
3 Months - 18 Years
>/= 18 Years
</= 5.0
</= 10.0
</=8.0
Amikacin Therapeutic Peak ug/mL:
0 Minutes - 18 Years
>/=18 Years
25.0-35.0
20.0-25.0
Ammonia, Plasma umol/L
18-72
Amylase U/L:
0 Minutes - 28 Days
28 Days - 71 Years
>/= 71 Years
5-65
25-125
20-160
Amylase Urine Random U/L
</=650
Amylase Urine Timed U/24 Hours
24-408
Page 8 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
Amylase Body Fluid
REFERENCE:
Peritoneal: Elevated at very high concentrations in
pancreatitis. At least several-fold times higher in fluid
of pancreatic origin compared to simultaneous values
in serum, even in cases of acute pancreatitis. Elevated
in pancreatic injury.
Pleural Fluid: May be high due to contamination with
salivary secretions and food in suspected esophageal
rupture.
Anion Gap
5-15
Antinuclear Antibody screen
Negative
Antinuclear Antibody Profile
Anti-SSA
<99 IU/mL
Anti-SSB
<99 IU/mL
Anti-Smith
<99 IU/mL
Anti-RNP
<99 IU/mL
Anti- Scl-70
<99 IU/mL
Anti-Jo1
<99 IU/mL
Anti-dsDNA
<99 IU/mL
Anti-Centromere Ab
<99 IU/mL
Anti-Histone
<99 IU/mL
Page 9 of 49
<100 Neg
100-120 Equivocal
>120 Pos
<100 Neg
100-120 Equivocal
>120 Pos
<100 Neg
100-120 Equivocal
>120 Pos
<100 Neg
100-120 Equivocal
>120 Pos
<100 Neg
100-120 Equivocal
>120 Pos
<100 Neg
100-120 Equivocal
>120 Pos
<100 Neg
100-120 Equivocal
>120 Pos
<100 Neg
100-120 Equivocal
>120 Pos
<100 Neg
100-120 Equivocal
>120 Pos
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
Anti-Streptolysin O (ASO) U/mL:
0 Minutes - 4 Days
4 Days - 18 Years
>/= 18 Years
REFERENCE:
Anti-Thrombin III Assay (ATIII)
77-131%
APT Fetal Hemoglobin
Absent
AST (SGOT) U/L
5-34
Barbituates, Urine Qualitative
Negative
Beta-Hydroxybutyric Acid
0-0.5 mmol/L
Bilirubin, Total mg/dL:
Male and Female:
O Minutes - 24 Hours
1 Year - 6 Years
24 Hours - 48 Hours
48 Hours - 5 Days
5 Days - 8 Days
8 Days - 6 Years
6 Years - 11 Years
11 Years - 15 Years
Male:
15 Years - 21 Years
Female:
15 Years - 21 Years
Male and Female:
>/=21 Years
Bilirubin, Direct mg/dL:
Male:
0 Day - 1 Month
1 Month - 12 Months
Female:
0 Day - 1 Month
1 Month - 12 Months
Male and Female:
1 Year - 11 Years
11 Years - 15 Years
Male:
</=99
</=251
</=199
<6.0
0.1-0.9
<10.0
<12.0
<10.0
0.1 - 0.9
0.1-1.1
0.2-1.1
0.2-2.0
0.2-1.4
0.2-1.2
</=1.2
0.1-0.8
</=1.0
0.1-0.5
0.1-0.4
0.1-0.5
Page 10 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
15 Years - 21 Years
Female:
15 Years - 21 Years
Male and Female:
>/=21 Years
REFERENCE:
0.1-0.7
Bilirubin Body Fluid
Peritoneal: Leakage from biliary ducts should result in
fluid levels of bilirubin several -fold higher in the fluid
than in serum from the patient. High Bilirubin
concentration is presumptive evidence for bile leakage
Bilirubin Cord Blood mg/dL
<2.0
Bilirubin Indirect mg/dL:
0.0-0.7
Blood Culture ID by PCR
Not Detected
BNP (Natriuretic Peptide) pg/mL:
0 Days - 11 Months
1 Year - 5 Years
6 Years - 10 Years
11 Years - 14 Years
15 Years - 20 Years
>/=21 Years
<24
<30
<15
<21
<20
<100
Bordetella pertussis DNA
Negative
Buprenorphine, Urine Qualitative
Negative
BUN (Blood Urea Nitrogen) mg/dL:
Male and Female:
0 Minutes - 1 Year
1 Year - 6 Years
6 Years - 11 Years
Male:
11 Years - 15 Years
15 Years - 21 Years
21 Years - 50 Years
>/= 50 Years
Female:
11 Years - 15 Years
15 Years - 21 Years
0.1-0.5
</=0.5
5-14
6-20
7-19
6-19
6-20
9-21
8-26
6-18
5-18
Page 11 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
21 Years - 50 Years
>/= 50 Years
REFERENCE:
7-19
10-20
BUN/Creatinine Ratio
10.0-24.0
CA 15-3 Level U/mL
<31.4
CA 125 Level U/mL
<35.1
Calcium mg/dL:
Male:
0 Days - 1 Year
Female:
0 Days - 1 Year
Male and Female:
1 Year - 11 Years
11 Years - 21 Years
Male:
21 Years - 60 Years
>/= 60 Years
Female:
>/21 Years
Calcium Urine Random
Calcium Urine 24 Hour:
CA Free Diet
Low to Average Intake
Average Intake
Calcium/Creatinine Ratio, Urine
9.2-11.2
10.0-11.2
9.2-10.4
8.8-10.4
8.4-10.2
8.8-10.0
8.4-10.2
No Reference Ranges Established
5-40 mg/24 hour
50–150 mg/24 hour
100–300 mg/24 hour:
Average (800 mg/day)
No Reference Ranges
Established
Calcium, Ionized (includes pre and post filter)
mmol/L
0-1 Months
1.0-1.5
1 Months-6 Months
0.95-1.5
>/=7 Months
1.16-1.32
Carbamazepine (Tegretol) Therapeutic ug/mL 4.0-12.0
Carcinoembryonic Antigen (CEA) ng/mL
</=5.0
Page 12 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
Cardiolipin Antibody IgG
REFERENCE:
0.00-19.99 GPL
Cardiolipin Antibody IgM
0.00-19.99 MPL
CD4 Level/ T&B Cell Enumeration Panel
(CD3, CD4, CD8, CD19, CD16/56) / T
Helper/Suppressor, Whole Blood(CD3, CD4,
CD8)
CD3 WB
0-3 Months
3-6 Months
6 Months - 1 Yr
1-2 Years
2-6 Years
6-12 Years
12-18 Years
>/= 18 Years
CD3 Cells/uL WB
0-3 Months
3-6 Months
6 Months - 1 Yr
1-2 Years
2-6 Years
6-12 Years
12-18 Years
>/= 18 Years
CD4 T Helper WB
0-3 Months
3-6 Months
6 Months - 1 Yr
1-2 Years
2-6 Years
6-12 Years
12-18 Years
>/= 18 Years
CD4 Cells/uL WB
0-3 Months
3-6 Months
6 Months - 1 Yr
1-2 Years
2-6 Years
6-12 Years
12-18 Years
53-84 %
51-77 %
49-76 %
53-75 %
56-75 %
60-76 %
56-84 %
58-84 %
2500 - 5500 Cells/uL
2500 - 5600 Cells/uL
1900 - 5900 Cells/uL
2100 - 6200 Cells/uL
1400 - 3700 Cells/uL
1200 - 2600 Cells/uL
1000 - 2200 Cells/uL
856 - 2237 Cells/uL
35-64 %
35-56 %
31-56 %
32-51 %
28-47 %
31-47 %
31-52 %
33.6-64.8 %
1600 - 4000 Cells/uL
1800 - 4000 Cells/uL
1400 - 4300 Cells/uL
1300 - 3400 Cells/uL
700 - 2200 Cells/uL
650 - 1500 Cells/uL
530 - 1300 Cells/uL
Page 13 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
>/= 18 Years
CD8 TSuppr WB
0-3 Months
3-6 Months
6 Months - 1 Yr
1-2 Years
2-6 Years
6-18 Years
>/= 18 Years
CD8 Cells/uL WB
0-3 Months
3-6 Months
6 Months - 1 Yr
1-2 Years
2-6 Years
6-12 Years
12-18 Years
>/= 18 Years
CD16/56 NK Cells WB
0-3 Months
3-6 Months
6 Months - 2 Yr
2-12 Years
12-18 Years
>/= 18 Years
CD16/56 Cells/uL WB
0-3 Months
3-6 Months
6 Months - 1 Yr
1-2 Years
2-6 Years
6-12 Years
12-18 Years
>/= 18 Years
CD19 TSuppr WB
0-3 Months
3-6 Months
6 Months - 1 Yr
1-2 Years
2-6 Years
6-12 Years
12-18 Years
>/= 18 Years
REFERENCE:
518 - 1472 Cells/uL
12 - 28 %
12 - 23 %
12 - 24 %
14 - 30 %
16 - 30 %
18 - 35 %
13 - 37.6 %
560 - 1700 Cells/uL
590 - 1600 Cells/uL
500 - 1700 Cells/uL
620 - 2000 Cells/uL
490 - 1300 Cells/uL
370 - 1100 Cells/uL
330 - 920 Cells/uL
205 - 924 Cells/uL
4 - 18 %
3 - 14 %
3 - 15 %
4 - 17 %
3 - 22 %
4.3 - 26.6 %
170 - 1100 Cells/uL
170 - 830 Cells/uL
160 - 950 Cells/uL
180 - 920 Cells/uL
130 - 720 Cells/uL
100 - 480 Cells/uL
70 - 480 Cells/uL
74 - 562 Cells/uL
6 - 32 %
11 - 41 %
14 - 37 %
16 - 35 %
14 - 33 %
13 - 27 %
6 - 23 %
5.7 - 24.9 %
Page 14 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
CD19 Cells/uL WB
0-3 Months
3-6 Months
6 Months - 1 Yr
1-2 Years
2-6 Years
6-12 Years
12-18 Years
>/= 18 Years
REFERENCE:
300 - 2000 Cells/uL
430 - 3000 Cells/uL
610 - 2600 Cells/uL
720 - 2600 Cells/uL
390 - 1400 Cells/uL
270 - 860 Cells/uL
110 - 570 Cells/uL
87 - 507 Cells/uL
Cell Count, CSF:
Nucleated Cells
0 - 12 Months
1-4 Years
4-12 Years
>/= 12 Years
0-30 /uL
0-20 /uL
0-10 /uL
0-8 /uL
RBC
0-1 /uL
Chloride mmol/L:
0 Minutes - 30 Days
>/= 30 Days
98-113
98-107
Chloride Urine Random
Chloride Urine Timed mmol/24 Hours:
0 Days - 28 Days
28 Days - 2 Years
2 Years - 18 Years
>/= 18 Years
No Reference Ranges Established
Chloride, Sweat
0-6 Months
7 Months-150 Years
Infants up to and including
6 months
of age: >/=60
0-30
mmol/L
0-40 mmol/L
Cholesterol mg/dL:
Male:
0 Days - 12 Months
Female:
0 Days - 12 Months
Male and Female:
1 Year - 2 Years
2 Years - 22 Years
No Reference Ranges Established
2-10
15-40
110-250; Varies greatly
with Cl Intake
47 - 205
93 - 223
114 - 220
<170
Page 15 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
>/=22 Years
Non-HDL Cholesterol, Calculated:
Ages 2 Years - 22 Years
Ages >/= 22 Years
HDL:
Male:
0 Days - 1 Year
Female:
0 Days - 1 Year
Male and Female:
1 Year - 2 Years
2 Years - 22 Years
>/= 22 Years
REFERENCE:
<200
Acceptable <120
Borderline 120-144
High >/=145
The goal for Non-HDL Cholesterol in persons with
high serum triglycerides can be set at 30 mg/dL higher
than that for LDL Cholesterol. For example, if the
LDL Cholesterol target goal is less than 100 mg/dL,
the corresponding Non-HDL Cholesterol target goal
would be less than 130 mg/dL.
14 - 63
19 - 69
25 - 73
Acceptable >45
Borderline 40-45
>/=60 mg/dL
VLDL
0 - 40 mg/dL
Cancer Antigen 125 (CA125) U/mL
</=35.0
Cancer Antigen 15-3 (CA 15-3)
</=31.3
CKMB ng/mL:
Female
Male
</=3.4
</=7.2
Clostridium Difficile Toxin B gene by PCR
Negative
CO2 mmol/L:
0 Days - 12 Months
1 Year - 6 Years
6 Years - 11 Years
11 Years - 14 Years
15 Years - 20 Years
21 Years - 61 Years
14-22
14-22
14-23
15-25
16-25
22-29
Page 16 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
>/= 61 Years
REFERENCE:
23-31
Complement, C-3 mg/dL:
Male and Female:
0 Days - 60 Days
61 Days - 90 Days
91 Days - 120 Days
121 Days - 150 Days
151 Days - 180 Days
181 Days - 210 Days
7 Months - 9 Months
10 Months - 11 Months
55 - 129
61 - 135
67 - 136
64 - 182
67 - 174
77 - 178
78 - 173
76 - 187
Male:
1 Year - 15 Years
15 Years - 80 Years
>/= 80 Years
80-170
82-185
79 - 152
Female:
1 Year - 15 Years
15 Years - 80 Years
>/= 80 Years
80-173
83-193
79 - 152
Complement, C-4 mg/dL:
Male and Female:
0 Days - 60 Days
61 Days - 90 Days
91 Days - 120 Days
121 Days - 150 Days
151 Days - 180 Days
181 Days - 210 Days
7 Months - 9 Months
10 Months - 11 Months
Male:
1 Year - 15 Years
15 Years - 80 Years
>/= 80 Years
Female:
1 Year - 15 Years
15 Years - 80 Years
>/= 80 Years
9.3 - 33.0
9.7 - 37.0
11.4 - 35.0
10.9 - 50.0
9.3 - 47.0
11.2 - 55.0
12.4 - 49.0
16.0 - 51.0
14.0 - 44.0
15.0 - 53.0
16.0 - 38.0
13.0 - 46.0
15.0 - 57.0
16.0 - 38.0
Complete Blood Count (CBC):
Page 17 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
WBC:
Male:
0-15 Days
15-31 Days
1-2 Months
2-3 Months
3-6 Months
6-24 Months
2-6 Years
6-12 Years
12-18 Years
>18 Years
Female
0-15 Days
15-31 Days
1-2 Months
2-3 Months
3-6 Months
6-24 Months
2-6 Years
6-12 Years
12-18 Years
>18 Years
RBC:
Male:
0-15 Days
15-31 Days
1-2 Months
2-6 Months
6-24 Months
2-6 Years
6-12 Years
12-18 Years
>18 Years
Female
0-15 Days
15-31 Days
1-2 Months
2-6 Months
6-24 Months
2-6 Years
6-12 Years
REFERENCE:
8.0-15.4 K/uL
7.8-15.9 K/uL
8.1-15.0 K/uL
6.5-13.3 K/uL
6.5-13.3 K/uL
6.0-13.5 K/uL
5.1-13.4 K/uL
4.3-11.0 K/uL
3.8-9.8 K/uL
3.7-10.9 K/uL
8.2 - 14.6 K/L
8.4 - 14.4 K/uL
7.1 - 14.7 K/uL
6.0 - 13.3 K/uL
6.0 - 13.3 K/uL
6.5 - 13.0 K/uL
4.9 - 13.2 K/uL
4.3 - 11.4 K/uL
4.2 - 9.4 K/uL
3.7 - 11.0 K/uL
4.10-5.55 M/uL
3.16-4.63 M/uL
3.02-4.22 M/uL
3.43-4.80 M/uL
4.03-5.07 M/uL
3.89-4.97 M/uL
3.96-5.03 M/uL
4.03-5.29 M/uL
3.71-5.77 M/uL
4.12-5.74 M/uL
3.32-4.80 M/uL
2.93-3.87 M/uL
3.45-4.75 M/uL
3.97-5.01 M/uL
3.84-4.92 M/uL
3.90-4.96 M/uL
Page 18 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
12-18 Years
>18 Years
HGB:
Male:
0-15 Days
15-31 Days
1-2 Months
2-6 Months
6-24 Months
2-6 Years
6-12 Years
12-18 Years
>18 Years
Female:
0-15 Days
15-31 Days
1-2 Months
2-6 Months
6 Months-6 Years
6-12 Years
12-18 Years
>18 Years
HCT:
Male:
0-15 Days
15-31 Days
1-2 Months
2-3 Months
3-6 Months
6-24 Months
2-6 Years
6-12 Years
12-18 Years
>18 Years
Female:
0-15 Days
15-31 Days
1-2 Months
2-3 Months
3-6 Months
6-24 Months
REFERENCE:
3.93-4.90 M/uL
3.74-4.94 M/uL
13.9-19.1 g/dL
10.0-15.3 g/dL
8.9-12.7 g/dL
9.6-12.4 g/dL
10.1-12.5 g/dL
10.2-12.7 g/dL
10.7-13.4 g/dL
11.0-14.5 g/dL
13.7-17.5 g/dL
13.4-20.0 g/dL
10.8-14.6 g/dL
9.2-11.4 g/dL
9.9-12.4 g/dL
10.2-12.7 g/dL
10.6-13.2 g/dL
10.8-13.3 g/dL
11.2-15.7 g/dL
39.8-53.6 %
30.5-45.0 %
26.8-37.5 %
28.6-37.2 %
28.6-37.2 %
30.8-37.8 %
31.0-37.7 %
32.2-39.8 %
33.9-43.5 %
40.1-51.0 %
39.6-57.2 %
32.0-44.5 %
27.7-35.1 %
29.5-37.1 %
29.5-37.1 %
30.9-37.9 %
Page 19 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
2-6 Years
6-12 Years
12-18 Years
>18 Years
MCV:
Male:
0-15 Days
15-31 Days
1-2 Months
2-6 Months
6-24 Months
2-6 Years
6-12 Years
12-18 Years
>18 Years
Female:
0-15 Days
15-31 Days
1-2 Months
2-6 Months
6-24 Months
2-6 Years
6-12 Years
12-18 Years
>18 Years
MCH:
Male:
0-15 Days
15-31 Days
1-2 Months
2-6 Months
6-24 Months
2-6 Years
6-12 Years
12-18 Years
>18 Years
Female:
0-15 Days
15-31 Days
1-2 Months
2-6 Months
REFERENCE:
31.2-37.8 %
32.4-39.5 %
33.4-40.4 %
34.1-44.9 %
91.3-103.1 fL
89.4-99.7 fL
84.3-94.2 fL
74.1-87.5 fL
69.5-81.7 fL
71.3-84.0 fL
74.4-86.1 fL
76.7-89.2 fL
79.0-96.2 fL
92.7-106.4 fL
90.1-103.0 fL
83.4-96.4 fL
74.8-88.3 fL
71.3-82.6 fL
72.3-85.0 fL
75.9-87.6 fL
76.9-90.6 fL
79.4-95.3 fL
31.3-35.6 pg
29.9-34.1 pg
27.8-32.0 pg
24.4-28.9 pg
22.7-27.2 pg
23.7-28.3 pg
24.9-29.2 pg
25.2-30.2 pg
25.7-32.2 pg
31.1-35.9 pg
30.4-35.3 pg
28.0-32.5 pg
24.4-29.5 pg
Page 20 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
6-24 Months
2-6 Years
6-12 Years
12-18 Years
>18 Years
MCHC:
Male:
0-15 Days
15-31 Days
1-2 Months
2-6 Months
6-24 Months
2-6 Years
6-12 Years
12-18 Years
>18 Years
Female:
0-15 Days
15-31 Days
1-2 Months
2-6 Months
6-24 Months
2-12 Years
12-18 Years
>18 Years
RDW-CV:
Male:
0-15 Days
15-31 Days
1-2 Months
2-6 Months
6-24 Months
2-6 Years
6-12 Years
12-18 Years
>18 Years
Female:
0-15 Days
15-31 Days
1-2 Months
2-6 Months
REFERENCE:
23.2-27.5 pg
23.7-28.6 pg
24.8-29.5 pg
24.8-30.2 pg
25.6-32.2 pg
33.0-35.7 g/dL
32.7-35.1 g/dL
32.3-34.8 g/dL
31.9-34.4 g/dL
31.6-34.4 g/dL
32.0-34.7 g/dL
32.2-34.9 g/dL
31.8-34.8 g/dL
32.2-36.5 g/dL
33.4-35.4 g/dL
33.2-35.0 g/dL
32.5-34.9 g/dL
32.1-34.4 g/dL
31.9-34.2 g/dL
31.8-34.6 g/dL
31.5-34.2 g/dL
32.2-35.3 g/dL
14.8-17.0 %
14.3-16.8 %
13.8-16.1 %
12.4-15.3 %
12.9-15.6 %
12.5-14.9 %
12.3-14.1 %
12.4-14.5 %
11.6-14.4 %
14.6-17.3 %
14.4-16.2 %
13.6-15.8 %
12.2-14.3 %
Page 21 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
6-24 Months
2-6 Years
6-12 Years
12-18 Years
>18 Years
MPV:
Male:
0-15 Days
15-31 Days
1-2 Months
2-6 Months
6-24 Months
2-6 Years
6-12 Years
12-18 Years
>18 Years
Female:
0-15 Days
15-31 Days
1-2 Months
2-6 Months
6-24 Months
2-6 Years
6-12 Years
12-18 Years
>18 Years
Platelet Count
Differential White Count (Manual):
Polys:
0-1 Months
1-23 Months
2-9 Years
10-17 Years
>17 Years
Lympocytes:
0-1 Months
1-23 Months
2-9 Years
10-17 Years
>17 Years
REFERENCE:
12.7-15.1 %
12.4-14.9 %
12.2-14.4 %
12.3-14.6 %
11.6-14.4 %
10.2-11.9 fL
10.1-12.1 fL
9.2-10.8 fL
8.9-10.6 fL
8.7-10.5 fL
9.0-10.9 fL
9.2-11.4 fL
9.6-11.8 fL
9.4-12.4 fL
10.4-12.0 fL
10.0-12.2 fL
9.4-11.1 fL
9.0-10.9 fL
8.8-10.6 fL
8.9-11.0 fL
9.3-11.3 fL
9.6-11.7 fL
9.4-12.3 fL
150-400 K/uL
32-62%
17-43%
30-61%
33-61%
40-70%
27-36%
30-64%
25-64%
25-45%
15-45%
Page 22 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
Monocytes:
0-1 Months
>1 Months
Bands:
0-1 Months
1-23 Months
>2 Years
REFERENCE:
Eosinophils
0-6%
Basophils
0-2%
Differential White Count (Automated):
Neutrophils:
0-1 Months
1-23 Months
2-9 Years
10-17 Years
>18Years
Lymphocytes:
0-1 Months
1-23 Months
2-9 Years
10-17 Years
>18Years
Monocytes:
0-1 Months
1 Months
0-20%
0-10%
0-18%
0-13%
0-10%
32-80%
17-56%
30-71%
33-71%
37-78%
27-36%
30-64%
25-64%
25-45%
15-45%
1-20%
4-13%
Differential White Count (Absolutes): K/uL
Male:
Absolute Neutrophils
Absolute Lymphocytes
Absolute Monocytes
Absolute Eosinophils
Absolute Basophils
Immature Granulocytes
1.78-5.38
1.32-3.57
0.30-0.82
0.04-0.54
0.01-0.08
0.00-0.03
Female:
Absolute Neutrophils
Absolute Lymphocytes
Absolute Monocytes
1.56-6.13
1.18-3.74
0.24-0.36
Page 23 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
Absolute Eosinophils
Absolute Basophils
Immature Granulocytes
Cortisol ug/dL:
Male and Female:
0 Days - 1 Year
1 Year - 6 Years
6 Years - 11 Years
11 Years - 15 Years
Male:
15 Years - 21 Years
Female:
15 Years - 21 Years
Male and Female >/=21 Years:
Before 10 am
After 10am
REFERENCE:
0.04-0.36
0.01-0.08
0.00-0.03
0.5-15.9
1.7-14.5
1.3-14.9
1.2-14.8
1.5-14.8
2.5-23.4
3.7-19.4
2.9-17.3
Cortisol Stimulation
A normal peak serum Cortisol is > 20 ug/dL.
C-Peptide ng/mL
0.78-5.19
Creatine Phosphokinase (CPK):
Male
Female
30-200
29-168
Creatinine mg/dL:
Male and Female:
0 Days - 1 Year
1 Year - 6 Years
Male:
6 Years - 11 Years
11 Years - 15 Years
15 Years - 21 Years
>/= 21 Years
Female:
6 Years - 11 Years
11 Years - 15 Years
15 Years - 21 Years
>/= 21 Years
0.30-0.50
0.40-0.60
0.50-0.70
0.50-0.80
0.60-1.00
0.70-1.30
0.40-0.70
0.50-0.80
0.60-0.90
0.60-1.10
Creatinine Urine Timed mg/dL (based on a
daily urine output of 1.5 L):
Page 24 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
Male
Female
REFERENCE:
63 - 166
47 - 110
Creatinine Urine Timed mg/24 Hours:
Male
Female
950-2490
710-1650
Creatinine Body Fluid
Pleural and Peritoneal: Urine extravasation will
usually present as a transudate with a high
concentration of creatinine and urea and a low
concentration of glucose and pH. Peritoneal Fluid
creatinine concentration will be markedly elevated (2.010.0 mg/dL), with the creatinine to serum creatinine
greater than 1.0. In the situation in which fluid
aspiration inadvertently consists of urine from the
bladder, the urea to creatinine ratio should be much
higher than for peritoneal fluid from which urea is
more readily absorbed than creatinine. Leakage of
urine should be suspected when the fluid has a high
creatinine concentration relative to that in serum from
a simultaneously collected blood specimen.
Creatinine Clearance:
Male
Female
66-163 mL/min per 1.73 m2
66-165 mL/min per 1.73 m2
Creatinine Urine, Random
No established Reference Range
C-Reactive Protein, Inflammation mg/L:
0 Days - 12 Months
1 Year - 6 Years
6 Years - 11 Years
11 Years - 15 Years
15 Years - 21 Years
>/= 21 Years
4.8-15.2
4.7-25.3
4.8-11.8
4.8-18.1
4.6-24.2
</=5.0
C-Reactive Protein, High Sensitivity:
Low Risk: <1.0 mg/L
Average Risk: 1.0-3.0
mg/L
High Risk: >3.0 mg/L
Cryptococcal Antigen, Blood/CSF
Negative
Cryptosporidium Stain
Absent
Page 25 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
REFERENCE:
Cyclosporine ng/mL
100-400
Therapeutic ranges are poorly defined. They are
related to clinical protocol, the organ transplanted, time
following transplantation, organ function, and
coadministration of other drugs. Ranges are also
method and specimen dependent.
Cytomegalovirus IgG
Negative
Cytomegalovirus IgM
Negative
D-Dimer
<0.5 ug/mL (FEU)
DHEA Sulfate ug/dL:
Male and Female:
0 Days - 12 Months
1 Year - 6 Years
6 Years - 11 Years
11 Years - 15 Years
Male:
15 Years - 21 Years
21 Years - 25 Years
25 Years - 35 Years
35 Years - 45 Years
45 Years - 55 Years
55 Years - 65 Years
65 Years - 70 Years
>/=70 Years
Female:
15 Years - 21 Years
21 Years - 25 Years
25 Years - 35 Years
35 Years - 45 Years
45 Years - 55 Years
55 Years - 65 Years
65 Years - 70 Years
>/=70 Years
Digoxin Therapeutic Range ng/mL
</=1087.0
</=91.0
</= 179.0
26.0-380.0
86.0-634.0
238.4-539.3
167.9-591.9
139.7-484.4
136.2-447.6
48.6-361.8
228.5-283.6
34.5 - 568.9
50.0-459.0
134.2-407.4
95.8-511.7
74.8-410.2
56.2-282.9
29.7-182.2
33.6-78.9
25.9 - 460.2
0.90-2.00
Page 26 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
Dilantin (Phenytoin) Therapeutic Range:
Total ug/mL
Free ug/mL
Free%
Drugs of Abuse Screen, Urine
Amphetamines, Qual
Benzodiazepines, Qual
Cannabinoids, Qual
Drug Scr Creatinine Urine
Cocaine Metabolites, Qual
Opiates, Qual
Methadone, Qual
Ecstasy (MDMA), Qual
DRVV (Dilute Russell Viper Venom)
EBV VCA IgG
EBV VCA IgM
Electrophoresis, Hemoglobin: %
Hgb A1
Hgb A2
Hgb F by age:
0-1 Month
1-3 Months
3-4 Months
REFERENCE:
10.0-20.0
1.5-3.0
10-20
Negative
Negative
Negative
Male: 63.00- 166.00
Female: 47.00-110.00
Negative
Negative
Negative
Negative
No evidence of
phospholipid inhibitor
<18.00 U/mL: Negative - Absence of detectable EBVVCA IgG antibodies 18.00-21.99 U/mL: Equivocal Repeat testing in 10-14 days may be helpful. >/=22.00
U/mL: Positive - Presence of detectable EBV-VCA
IgG antibodies. A positive result indicates current or
past exposure to Epstein-Barr virus.
<36.00 U/mL: Negative - Absence of detectable EBVVCA IgM antibodies. 36.00-43.99 U/mL: Equivocal Repeat testing in 10-14 days may be helpful. >/=44.00
U/mL: Positive - Presence of detectable EBV-VCA
IgM antibodies. Specific IgM antibodies are usually
detected in patients with recent primary infection and
may be found in patients with reactivated infections.
96.0-98.0
1.5-4.0
% Hgb F
64.0-77.0
42.0-64.0
7.0-42.0
Page 27 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
4 Months-1 Year
1-18 Years
>/= 18 Years
REFERENCE:
2.0-7.0
0.0-2.0
<0.5
Electrophoresis, Protein Urine:
Albumin
Alpha 1
Alpha 2
Beta
Gamma
Not Detected
Not Detected
Not Detected
Not Detected
Not Detected
Electrophoresis, Protein Serum:
Albumin
Alpha 1
Alpha 2
Beta
Gamma
Albumin/Globulin
3.0-5.05 g/dL
0.13-0.36 g/dL
0.57-1.22 g/dL
0.69-1.33 g/dL
0.63-2.00 g/dL
0.92-1.86 g/dL
Eosinophil Count
0.04-0.54 K/uL
Estradiol pg/mL:
Males:
0 Days - 1 Year
1 Year - 6 Years
6 Years - 11 Years
11 Years - 15 Years
15 Years - 21 Years
>/= 21 Years
8.3-23.3
4.2-22.9
4.0-18.9
7.8-30.9
8.1-49.6
11.0-44.0
Females:
0 Days - 1 Year
1 Year - 6 Years
6 Years - 11 Years
11 Years - 15 Years
15 Years - 21 Years
>/= 21 Years:
Follicular Phase
Mid-Cycle
Luteal
Post Menopausal not on HRT
Post Menopausal on HRT
7.7-42.5
8.6-26.6
8.3-37.5
7.3-96.6
9.3-259.7
21.0-251.0
38.0-649.0
21.0-312.0
<10.0 - 28.0
<10.0- 144.0
Page 28 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
Factor II,V,VII,VIII, IX, X, XI,XII
REFERENCE:
50-150%
Factor V Leiden Mutation
Negative
Factor XIII
clot present
Fat, Fecal (Qualitative)
Small amount of neutral fat is normal
Fecal Lactoferrin
Negative
Ferritin ng/mL:
Male and Female:
0 Days - 1 Year
1 Year - 6 Years
6 Years - 11 Years
11 Years - 15 Years
15 Years - 21 Years
Male >/=21 Years
Female >/=21 Years
9-72
3-127
9-185
6-216
4-207
22-275
5-204
Fetal Fibronectin
Negative
Fetal Hgb Flow Marker
<0%
Fibrinogen
244-498 m/dL
Folate ng/mL
7-31.4
FSH mIU/mL:
Males:
0 Days - 1 Year
1 Year - 6 Years
6 Years - 11 Years
11 Years - 15 Years
15 Years - 21 Years
>/= 21 Years
Females:
0 Days - 1 Year
</=3.50
</=1.45
</=3.04
0.36-6.29
0.49-9.98
0.95-11.95
1.84-20.26
Page 29 of 49
Normal clot stable for
>24 hours. Dissolution of
clot in 24 hours indicates
marked deficiency of
Factor XIII (<5%
activity).
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
1 Year - 6 Years
6 Years - 11 Years
11 Years - 15 Years
15 Years - 21 Years
Normally Menstruating Females:
Follicular Phase
Mid-Cycle
Luteal
Post Menopausal
REFERENCE:
0.6-6.12
</=4.62
0.19-7.97
0.57-8.77
GC and Chlamydia DNA by PCR
Negative
GC DNA by PCR
Negative
Chlamydia DNA by PCR
Negative
Gentamicin ug/mL:
Therapeutic Trough:
0-3 Months
3 Months - 18 Years
>/= 18 Years
Therapeutic Peak:
0-18 Years
>/=18 Years
Random
3.03-8.08
2.55-16.69
1.38-5.47
26.75-133.41
<1.1
<2.1
<2.0
5.0-12.0
>5.0
Apply to nomogram. Please contact pharmacy with
questions.
GFR
GFRA (African American)
>60
>60
GGT (Gamma Glutamyltransferase) U/L
Male
Female
12-64
9-36
GI Panel by PCR
Not Detected
Giardia/Cryptosporidia Antigen/
Cryptosporidium Ag/ Giardia Ag
Negative
Gliadin Ab, IgA
< 6.9 Elia u/mL
Page 30 of 49
Negative 0.1-6.9
Equivocal 7.0-10.0
Positive >10.0
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
Gliadin Ab, IgG
REFERENCE:
< 6.9 Elia u/mL
Glomerular Basement Membrane Antibody
(GBM)
0-99 AU/mL
Glucose mg/dL:
0-30 day
>31 day
Random
CSF
Gestational Screen 1 Hours
Post Prandial:
Non-Pregnant Adults with Diabetes
Gestational Diabetes Screen
Glucose Tolerance, Gestational:
The diagnosis of Gestational Diabetes
Mellitus is made if at least two of the
following four plasma glucose levels are met
or exceeded:
Glucose Tolerance:
Fasting
2 Hour Glucose
3 Hour Glucose
50-80
70-99
100-125 Impaired Fasting
70-139
40-70
>/=140
<180
More or less stringent
glycemic goals may be
appropriate for individual
patients.
For values >/= 140 the
American Diabetes
Association (ADA)
recommends a 100g Oral
Glucose Tolerance Test.
Fasting Glucose: 95
1 Hour Glucose: 180
2 Hour Glucose 155
3 Hour Glucose 140
70-99 Normal
100-125 Impaired
>/=126 Provisional
Diagnosis of Diabetes
70-130 Normal
140-190 Impaired
>/= 200 Provisional
Diagnosis of Diabetes
No Reference Ranges per
ADA guidelines
Page 31 of 49
Negative 0.4-6.9
Equivocal 7.0-10.0
Positive >10.0
<100 Negative
100-120 Equivocal
>120 Positive
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
4 Hour Glucose
5 Hour Glucose
REFERENCE:
No Reference Ranges per
ADA guidelines
No Reference Ranges per
ADA guidelines
Body Fluid
Pleural Fluid: <60 mg/dL is suggestive of an empyema
or parapneumonic effusion.
Synovial Fluid Reference Range: Plasma-synovial
fluid difference </= 10.0 mg/dL. Abnormal: Serumsynovial fluid difference 20-25 mg/dL or more.
NOTE: Postprandial equilibrium between plasma and
synovial fluid may require several hours. At
equilibrium, the synovial fluid glucose level is
normally 10 mg/dL or less than the plasma level. In
general, noninflammatory and hemorrhagic joint
disorders have synovial fluid glucose levels 10-20
mg/dL or less, respectively, than the simultaneously
measured plasma levels. Inflammatory disorders are 040 mg/dL below the plasma level, while infectious and
crystal-induced are 20-100 mg/dL and 0-80 mg/dL less
than the plasma level, respectively.
Group B Strep by Rapid PCR
Negative
H Pylori biopsy screen
Negative
Haptoglobin mg/dL:
0 Days - 12 Months
1 Year - 5 Years
6 Years - 10 Years
11 Years - 14 Years
15 Years - 20 Years
21 Years - 60 Years Male
21 Years - 60 Years Female
>/=61 Years Male
>/=61 Years Female
<223
<244
<209
<227
<237
14-258
35-250
40-268
63-273
HCGQ (Beta HCG) Quantiative mIU/mL:
Weeks Post Last Menstural Period:
1-10
11-15
16-22
<1.20 - 231,000
16,996 - 234,990
6,860 - 50,064
Page 32 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
23-40
Non-pregnant Female
REFERENCE:
1,583-49,413
<5
Hemoglobin A1C %
0-18 years
>/=19 years
Estimated Glucose Average: mg/dL
4.8-7.4
4.0-5.6
Refer to Glucose
Hepatitis A IgG Antibody
May be Reactive with Past
Infection or Vaccination
Hepatitis A Antibody IgM
Non Reactive
Hepatitis B Surface Antigen
Non Reactive
Hepatitis B Antibody IgG
May be Reactive with Past
Infection or Vaccination
Hepatitis Core IgM
Non Reactive
Hepatitis Core Total Ab
Non Reactive
Hepatitis C RNA by PCR, Quant
Not Detected
HIV, Rapid Exposure w/reflex HIV 1/2 Ab
Confirm
Non Reactive
HIV, Ag w/HIV1 & 2 Antibodies
Non Reactive
Homocystine umol/L
Male
Female
5.5 - 16.2
4.4 - 13.6
HSV DNA by PCR
Not Detected
Immunoglobulin A (IgA) mg/dL:
Male and Female:
0 Minutes - 2 Months
3 Months - 12 Months
Male:
1 Year - 11 Years
12 Years - 59 Years
1-34
8-91
21 - 291
63 - 484
Page 33 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
>/= 60 Years
Female:
1 Year - 11 Years
12 Years - 59 Years
>/= 60 Years
REFERENCE:
101 - 645
Immunoglobulin E (IgE): Allergy Levels
Less than 0.1 kU/L - No significant level detected
Immunoglobulin G (IgG) mg/dL:
Male:
0 Minutes - 30 Days
1 Month - 11 Months
12 Months - 23 Months
>/= 2 Years
Female:
0 Minutes - 30 Days
1 Month - 11 Months
12 Months - 23 Months
>/= 2 Years
Immunoglobulin M (IgM) mg/dL:
Male and Female:
0 Days - 3 Months
Male:
3 Months - 23 Months
1 Year - 11 Years
>/= 12 Years
Female:
3 Months - 23 Months
1 Year - 11 Years
>/= 12 Years
21 - 282
65 - 421
69 - 517
397 - 1765
205 - 948
475 - 1210
540-1822
391 - 1737
203 - 934
483 - 1226
552 - 1631
6 - 21
17 - 143
41 - 183
22 - 240
17 - 150
47 - 240
33 - 293
India Ink Prep
Negative
Insulin, Fasting
3.0-19.0 uU/mL
Iron ug/dL:
Male and Female:
0 Days - 11 Months
1 Year - 5 Years
6 Years - 10 Years
11 Years - 14 Years
15 Years - 20 Years
20 - 154
10 - 151
7 - 148
19 - 156
15 - 156
Page 34 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
Male:
>/=21 Years
Female:
>/=21 Years
REFERENCE:
Iron Binding Capacity (TIBC) ug/dL
250-450
LAP (Leukocyte Alkaline Phosphatase)
15-100 (score)
Lactic Acid,Plasma mmol/L:
Plasma
CSF
0.5-2.2
0.6-2.2
Lactate Dehydrogenase (LDH) U/L:
Serum
Body Fluid
Lamellar Bodies: K/uL
Mature Lung
Transitional Lung
Immature Lung
LDL mg/dL:
0 Days - 1 Year
1 Year - 2 Years
2 Years - 22 Years
>/=22 Years
65 - 175
50 - 170
125 - 220
125 - 220
Ratio of Pleural Fluid LDH to a simultaneously
collected Serum Protein >0.6 is predictive of an
exuate. Synovial Fluid: Studies indicate that LDH
levels 400-700 U/L correspond to moderate disease
activity. Levels 750 U/L indicate high inflammatory
activity.
>/= 60
15-59
0-14
17 - 151
59 - 153
Acceptable <110
Optimal
<100
Near or Above optimal 100-129
Legionella Antigen, Urine
Negative
Luteinizing Hormone (LH) mIU/mL:
Female:
0 Days - 12 Months
1 Year - 5 Years
6 Years - 10 Years
11 Years - 14 Years
15 Years - 20 Years
<3.30
<0.28
<0.47
<15.27
<15.98
Page 35 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
Normally Menstruating Females:
Follicular Phase
Mid-Cycle Peak
Luteal Cycle
Postmenopausal without Hormone
Therapy
Male:
0 Days - 12 Months
1 Year - 5 Years
6 Years - 10 Years
11 Years - 14 Years
15 Years - 20 Years
>/= 21 Years
REFERENCE:
1.80 - 11.78
7.59 - 89.08
0.56 - 14.00
5.16 - 61.99
<6.35
<0.93
<1.04
<5.37
<4.94
0.57 - 12.07
Lipase U/L:
0 Days - 11 Months
1 Year - 5 Years
6 Years - 10 Years
11 Years - 20 Years
>/= 21 Years
<42
5 - 63
5 - 51
<44
8 - 78
Lipid Laden Macrophage
Negative
Lithium Therapeutic Range mmol/L
Acute Mania: 0.5 - 1.2
Maintenance: 0.6 - 1.0
Low Molecular Weight Heparin:
Low therapeutic
High therapeutic
0.2-0.4 IU/mL
0.5-1.2 IU/mL
Magnesium mg/dL ;
0 Days - 11 Months
1 Year - 5 Years
6 Years - 10 Years
11 Years - 20 Years
>/= 21 Years
Magnesium Urine, Random
Magnesium Urine, Timed mg/24 hr
1.9 - 3.2
1.9 - 3.4
1.9 - 3.6
1.9 - 2.4
1.6 - 2.6
No Reference Range
73 - 122
Meningitis/Enchephalitis Panel by PCR, CSF Not Detected
Microalbumin,Urine:
Random
Timed per Minute
<1.9 mg/dL
<20 ug/min
Page 36 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
Timed per 24 Hr
REFERENCE:
<30 mg/24 Hr
Microalbumin/Urine Creatinine Ratio
<30 mg/g creatinine
Monotest
Negative
MPO/PR-3 (ANCA) Antibodies
Myeloperoxidase Antibody
0-99 AU/mL
Serine Protease 3 Antibody
0-99 AU/mL
Mumps IgG
Mycobacterium Tuberculosis by PCR
<9: Negative - No current
or previous infection. Such
Not Detected
Mycoplasma Pneumoniae
Negative
Myeloperoxidase Antibody
0-99 AU/mL
Neisseria Gonorrhoea
Negative
Nitrites, Urine
Negative
Occult Blood, Fecal
Gastric/Vomitus occult blood
Negative
Negative
Osmolality: mOSM/kgH20
Blood
Urine
270-295
50-1200 Depending on fluid intake
Average fluid intake: 300-900
After 12 Hr fluid restriction: >850
P2Y12 Platelet Function
182-335
Parathyroid Hormone, Intact pg/mL
8.7 - 77.1
PCR, Rapid MRSA
Negative
Phencyclidine (PCP), Urine Qualitative
Negative
Phenobarbital Therapeutic Range ug/mL
15-40
pH:
Page 37 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
Urine
Gastric
Phosphorus mg/dL:
Male and Female:
0 Days - 11 Months
1 Year - 5 Years
6 Years - 10 Years
Male:
11 Years - 14 Years
15 Years - 20 Years
Female:
11 Years - 14 Years
15 Years - 20 Years
Male and Female:
>/= 21 Years
REFERENCE:
4.5-8.0
<4.0
4.8 - 7.8
4.4 - 6.8
3.8 - 6.2
3.8 - 6.1
2.7 - 5.4
3.0 - 5.8
3.3 - 5.0
2.3 - 4.7
Pinworm Prep/Exam
Not Present
Platelet Function Screen:
Col/Epi
Col/ADP
<194 sec
<103 sec
Potassium (K+) mmol/L:
Serum:
0 Days - 27 Days
28 Days - 23 Months
2 Years - 17 Years
>/= 18 Years
Plasma:
Male
Female
Potassium Urine, Random mmol/L
Potassium Urine, Timed mmol/24 hrs
Prealbumin mg/dL:
Male and Female:
0 Days - 11 Months
1 Year - 5 Years
6 Years - 10 Years
11 Years - 14 Years
15 Years - 20 Years
Male:
3.7 - 5.9
4.1 - 5.3
3.4 - 4.7
3.5 - 5.1
3.5 - 4.5
3.4 - 4.4
No Reference Ranges
Established
25-125
<25.3
8.7 - 26.6
8.1 - 27.8
14.2 - 32.6
<35.2
Page 38 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
21 Years - 60 Years
>/=61 Years
Female:
21 Years - 60 Years
>/=61 Years
REFERENCE:
18.0 - 45.0
16.0 - 42.0
Procalcitonin
<0.1 ng/mL
Progesterone ng/mL:
Male
Normal Menstruating Females:
Follicular Phase:
Luteal Phase:
Postmenopausal Females:
Pregnant Females:
First Trimester:
Second Trimester:
Third Trimester:
Prolactin ng/mL:
Male and Female:
0 Days - 11 Months
1 Year - 5 Years
6 Years - 10 Years
Male:
11 Years - 14 Years
15 Years - 20 Years
>/=21 Years
Female:
11 Years - 14 Years
15 Years - 20 Years
>/=21 Years
16.0 - 38.0
14.0 - 37.0
<0.3
<0.4
1.2 - 15.9
<0.3
2.8 - 147.3
22.5 - 95.3
27.9 - 242.5
3.3 - 109.7
3.9 - 31.5
2.9 - 35.0
3.5 - 16.3
4.6 - 21.0
3.5 - 19.4
4.6 - 49.1
4.2 - 117.9
5.2 - 26.5
Protein C Activity
70-161%
Protein S Activity
70-140%
Protein,Total mg/dL:
Serum:
0 Days - 11 Months
1 Year - 5 Years
6 Years - 10 Years
11 Years - 14 Years
4.9 - 7.3
6.2 - 8.0
6.6 - 8.6
6.4 - 8.5
Page 39 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
15 Years - 60 Years
>/=61 Years
Protein, Total Fluid mg/dL
REFERENCE:
6.4 - 8.3
6.2 - 8.1
Pleural and Pericardial: Transudate effusions have a
low concentration of Total Protein. Exudate effusions
have a high concentration of Total Protein. Serous
fluid Total Protein values >/=3.0 g/dL separate
exudates from transudates. A ratio of serous fluid total
protein to a simultaneously collected serum protein of
>/=0.5 is predictive of an exudate.
Protein, Total CSF:
0 Days - 30 Days
>/= 1 Month
20 - 80
15 - 45
Protein, Total Urine, 24 Hr
<300 mg/24hr; 50-80 mg/24hr at rest
Protein, Total Urine, Random mg/dL
<15
Protein/Creatinine Ratio, Urine
< 200 mg/g
Prothrombin Time (PTINR)
12.0-14.5 Seconds
PT Mixing Study
No Inhibitor Detected
PTT
23.9-36.6 Seconds
PTT Mixing Study
No Inhibitor Detected
PSA (Prostate Specific Antigen):
Total ng/mL
Free ng/mL
PSA, Free %
</=4.00
>2.50
</=26.0
Rapid Influenzae A & B Antigen Screen
Negative
Rapid Strep Grp A Screen
Negative
Respiratory Panel by PCR
Not Detected
Reticulocyte Count (Automated)
Retic %
Male and Female:
0.5-1.8
Page 40 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
0-4 Days
4-31 Days
31-61 Days
61 Days-6 Months
6 Months-2 Years
2-6 Years
6-12 Years
12-18 Years
>/=18Years
Retic Absolute M/uL
Male and Female:
0-4 Days
4-31 Days
31-61 Days
61 Days-6 Months
6 Months-2 Years
2-6 Years
6-12 Years
12-18 Years
Male:
>/=18Years
Female:
>/=18Years
Immature Retic Fraction (IRF) %
Male:
0 Minutes-6 Months
6 Months-2 Years
2 Years-6 Years
6 Years-12 Years
12 Years-18 Years
>/=18 Years
Female:
0 Minutes-6 Months
6 Months-2 Years
2 Years-6 Years
6 Years-12 Years
12 Years-18 Years
>/=18 Years
REFERENCE:
3.5-5.4
1.1-2.4
2.1-3.5
1.6-2.7
1.0-1.8
0.8-1.5
1.0-1.9
0.9-1.5
0.5-1.8
Rheumatoid Factor IU/mL
<30
RPR Serological Test for Syphilis
Nonreactive
0.1475-0.2164
0.0513-0.1104
0.0518-0.0779
0.0482-0.0882
0.0435-0.1111
0.0364-0.0680
0.0424-0.0702
0.0416-0.0651
0.0260-0.0950
0.0164-0.0776
2.3-13.4
11.0-26.9
8.5-30.6
7.1-33.0
7.3-30.3
5.2-29.4
2.3-13.4
10.7-30.5
8.4-27.3
5.9-26.6
8.3-30.0
7.5-27.3
3.0-15.9
Page 41 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
RSV antigen
REFERENCE:
Negative
Rubeola IgG
<25: Negative - No current or previous infection. Such
indiviuals are presumed ot b esusceptible to primary
infection.
25 to 30: Equivocal - Should be tested by an alternate
serologic procedure. Additionally specimens which
ramin equivocal after repeat testing should be reevaluated by drawing another sample one to three
weeks later.
>30: Positive - A positive test result indicates a current
or previous infection and is consistent with immunity.
Salicylate, Therapeutic Range mg/dL
10-30
Sedimentation Rate: (Palmetto Health
Richland Rapid Care, Palmetto Health Baptist
and Palmetto Health Baptist Parkridge):
Male
0-50 Years
50-85 Years
85+ Years
Female
0-50 Years
50-85 Years
85+ Years
0-15 mm/hr
0-20 mm/hr
0-30 mm/hr
0-20 mm/hr
0-30 mm/hr
0-42 mm/hr
Sedimentation Rate: (Palmetto Health Central
Laboratory):
Male:
0-1 Years
1-12 Years
12-50 Years
>/=50 Years
Female:
0-1 Years
1-12 Years
12-50 Years
>/=50 Years
0-2 mm/hr
3-14 mm/hr
0-15 mm/hr
0-20 mm/hr
0-2 mm/hr
3-13 mm/hr
0-20 mm/hr
0-30 mm/hr
Page 42 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
Semen Analysis:
pH
Volume
Count
Viscosity
Liquefaction
Motility
Sex Hormone Binding nmol/L:
Male
Female
Sodium mmol/L;
0 Days - 27 Days
28 Days - 23 Months
2 Years - 17 Years
>/=18 Years
Sodium Urine, Random
Sodium Urine, Timed mmol/24 Hours
Male:
6 Years - 9 Years
10 Years - 13 Years
Female:
6 Years - 9 Years
10 Years - 13 Years
Male and Female:
>/=14 Years
REFERENCE:
>7.2
1.5-5.0 mL
60-200 million/mL
Normal-High Normal
Complete
50% or more motile with forward progression within
60 minutes of ejaculation.
11.2 - 78.1
11.7 - 137.2
133 - 146
139 - 146
138 - 145
136 - 145
No Reference Ranges
Established
41 - 115
63 - 177
20 - 69
48 - 168
40-220
Special Fungal/ Pneumocystis Stain
Negative
Specific Gravity, Urine
1.001-1.035
Strep Pneumoniae Antigen, Urine / CSF
Negative
Tacrolimas(FK506) ng/mL - Whole Blood
Trough:
Adult Heart Transplant 1 to 3 Months
Adult Heart Transplant >/=4 Months
10 - 20
5-15
Adult Kidney Transplant
In combination with Azathioprine:
Months 1 to 3
7-20
Page 43 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
Months 4 to 12
REFERENCE:
5-15
In combination with mycophenolate
mofetil/IL-2 receptor antagonist (e.g.
daclizumab) 1 to 12 Months
4-11
Tacrolimus ER (Astagraf XL) with
basiliximab induction:
Month 1:
Months 2 to 6
> 6 Months
7-15
5-15
5-10
Tacrolimus ER (Astagraf XL) without
induction:
Month 1
Months 2 to 6
> 6 Months
10-15
5-15
5-10
Liver Transplant (Pediatric and Adult)
Months 1 to 12
T3, Free pg/mL:
Male and Female:
0 Days - 11 Months
1 Year - 5 Years
6 Years - 10 Years
Male:
11 Years - 14 Years
15 Years - 20 Years
Female:
11 Years - 14 Years
15 Years - 20 Years
Male and Female:
>/=21 Years
T3, Total ng/dL:
Male:
0 Days - 12 Months
Female:
0 Days - 12 Months
Male and Female:
1 Year - 6 Years
6 Years - 11 Years
5 - 20
2.20 - 4.90
2.80 - 4.70
2.80 - 4.40
2.40 - 4.50
1.90 - 4.40
2.20 - 4.20
2.20 - 3.90
1.71 - 3.71
61 - 204
102 - 229
106 - 203
104 - 183
Page 44 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
11 Years - 15 Years
15 Years - 21 Years
>/=21 Years
REFERENCE:
68 - 186
71 - 175
58 - 159
T4, Total ug/dL
4.87 - 11.72
T4, Free (Free Thyroxine/FT4) ng/dL
Male:
0 Days - 11 Months
1 Year - 5 Years
Female:
0 Days - 11 Months
1 Year - 5 Years
Male and Female:
6 Years - 10 Years
11 Years - 14 Years
15 Years - 20 Years
>=21 Years
0.92-1.83
0.86-1.62
0.85-1.59
0.91-1.44
0.84-1.47
0.78-1.31
0.79-1.34
0.70-1.48
Tegretol (Carbamazepine) Therapeutic Range 4-12 ug/mL
Testosterone ng/dL:
Male:
21 Years - 49 Years
>/= 50 Years
253-803
248-674
T-Helper Lymphocytes Absolute
0-3 Months
3-6 Months
6-12 Months
12-24 Months
2-6 Years
6-12 Years
12-18 Years
>18 Years
1600-4000 Cells/uL
1800-4000 Cells/uL
1400-4300 Cells/uL
1300-3400 Cells/uL
700-2200 Cells/uL
650-1500 Cells/uL
530-1300 Cells/uL
518-1472 Cells/uL
Theophylline ug/mL Therapeutic Range
5-20
Thrombin Clot Time
0-21 sec
Thyroglobulin Antibody IU/mL
<4.1
Page 45 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
Thyroperoxidase Antibody U/mL
Tobramycin Therapeutic Range ug/mL:
Random
Through:
0-2 Months.
3 Months.-17 Years.
>/=18 Years.
Peak:
0-17 Years.
>/=18 Years.
Transferrin mg/dL:
Male and Female:
0 Days - 11 Months
1 Year - 5 Years
Male:
6 Years - 10 Years
11 Years - 14 Years
15 Years - 20 Years
21 Years - 59 Years
60 Years - 80 Years
Female:
6 Years - 10 Years
11 Years - 14 Years
15 Years - 20 Years
21 Years - 59 Years
60 Years - 80 Years
Transferrin Saturation %:
Male
Female
Triglycerides:
0 Days - 11 Months
1 Year - 5 Years
6 Years - 10 Years
11 Years - 14 Years
15 Years - 20 Years
>/=21 Years
REFERENCE:
<5.6
Apply to nomogram. Please contact pharmacy with
questions.
<1.1
<2.1
<2.0
5.0-12.0 ug/mL
>5 ug/mL
133 - 332
204 - 366
217 - 321
181 - 353
183 - 363
174 - 364
163 - 344
177 - 371
200 - 367
193 - 421
180 - 382
173 - 360
20 - 50
15 - 50
42 - 295
40 - 242
41 - 282
41 - 312
42 - 214
<150 mg/dL Normal
150-199 mg/dL Borderline High
200-499 mg/dL High
Page 46 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
REFERENCE:
>/= 500 mg/dL Very High
Troponin ng/mL
<0.03
TSH (Thyroid Stimulating Hormone)
uIU/mL:
Male and Female:
0 Days - 11 Months
Male:
1 Year - 5 Years
Female:
1 Year - 5 Years
Male and Female:
6 Years - 10 Years
Male:
11 Years - 14Years
Female:
11 Years - 14 Years
Male and Female:
>/=15 Years
0.9000 - 5.4000
0.7000 - 4.5000
0.7000 - 4.8000
0.6600 - 3.9000
0.6000 - 3.6000
0.5000 - 4.1000
0.3500 - 4.9400
Unfractionated Heparin Anti-Xa Therapeutic 0.3-0.7 IU/ml
Range
Urea Nitrogen, Blood (BUN) mg/dL:
Male and Female:
0 Days - 11 Month
1 Year - 5 Years
6 Years - 10 Years
Male:
11 Years - 14 Years
15 Years - 20 Years
21 Years - 49 Years
>/=50 Years
Female:
11 Years - 14 Years
15 Years - 20 Years
21 Years - 49 Years
>/=50 Years
Urea Nitrogen, Urine:
Random
6 Hour
5 - 14
6 - 20
7 - 19
6 - 19
6 - 20
9 - 21
8 - 26
6 - 18
5 - 18
7 - 19
10 - 20
No Reference Ranges
Establishedmg/6 Hours; 12000 - 20,000 mg/24 Hours
3000-5000
Page 47 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
Body Fluid
Uric Acid mg/dL:
Male:
0 Days–29 Days
30 Days - 3 Months
4 Months - 6 Months
7 Months - 11 Months
12 Months - 23 Months
2 Years - 17 Years
>/= 18 Years
Female:
0 Days–29 Days
30 Days - 3 Months
4 Months - 6 Months
7 Months - 11 Months
12 Months - 23 Months
2 Years - 17 Years
>/= 18 Years
Urinalysis w/Microscopy:
Spec Gravity
Urine Ph
Urine Glucose
Urine Protein
Urine Ketone
Urine Bilirubin
Urine Blood
Urine Nitrite
Urine Urob
Leuk Esterase
Urinalysis Microscopic Exam
WBC’s:
RBC’s:
Epithelial Cells:
Bacteria:
Hyaline Casts:
Vaginitis Panel by PCR
REFERENCE:
Pleural and Peritoneal: Urine extravasation will
usually present as a transudate with a high
concentration of creatinine and urea and a low
concentration of glucose and pH.
1.2-4.9
1.3-5.3
1.4-6.4
1.4-6.7
1.7-5.0
2.0 - 5.5
3.5 - 7.2
1.3 - 6.2
1.3 - 5.8
1.3 - 6.2
1.4 - 6.2
1.7-5.0
2.0 - 5.5
2.6 - 6.0
1.001-1.035
5-9
Negative
Negative
Negative
Negative
Negative
Negative
0.1-1.9 mg/dL
Negative
0-5 /hpf
0-3 /hpf
0-7 /lpf
None seen
0-5 /lpf
Negative
Page 48 of 49
Laboratory Form PH Reference and Therapeutic Range Summary
PROCEDURE:
Valproic Acid Therapeutic Range ug/mL
REFERENCE:
50-125
Vancomycin Trough Therapeutic Range
ug/mL:
Trough
Peak
10.0-20.0
30.0 - 50.0
Varicella Zoster, IgG
Vitamin B12 pg/mL
< 135: Negative - No
current or previous
</= 0.90: Negative - no
detectable IgM antibodies
213 - 816
Vitamin D 25-Hydroxy Level ng/mL
30.0 - 100.0
VLDL mg/dL
<40
vWF Antigen (Factor VIII Related Antigen)
>50%
Wet Prep
Non Seen/ Not Present
Varicella Zoster, IgM
Page 49 of 49